文献速递头颈部肿瘤放疗

普伐他汀逆转头颈癌患者已形成的放射性皮肤及皮下纤维化:生物学驱动的2期临床试验Pravacur结果

Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-02-15

PRAVACUR 2期试验评估普伐他汀对头颈鳞癌放疗和/或放化疗后已形成的≥2级皮肤及皮下放射性纤维化的疗效。60例患者接受普伐他汀40 mg/d治疗12个月,可评估的42例中15例(35.7%)RIF厚度减少≥30%,50%患者RIF严重程度下降,耐受性良好。

要点

  • 普伐他汀40 mg/d治疗12个月可使35.7%患者RIF厚度减少≥30%。
  • 12个月临床评估时50%患者RIF严重程度下降。
  • 普伐他汀耐受性良好,3级毒性仅肌痛1例。

核心结论

  • 这项2期前瞻性研究支持放射性纤维化可逆转的观点,显示普伐他汀(40 mg/d,12个月)对头颈鳞癌放疗后≥2级皮肤及皮下纤维化是有效的抗纤维化药物。

研究设计与样本

  • PRAVACUR 2期试验(NCT01268202),评估普伐他汀作为抗纤维化药物对头颈鳞癌放疗和/或放化疗后已形成的皮肤及皮下放射性纤维化的疗效。
  • 主要纳入标准为头颈鳞癌处于缓解期、≥2级颈部皮肤及皮下RIF(NCI CTCAE 4.0版)、当前未使用他汀类或贝特类药物。
  • 患者接受普伐他汀40 mg/d治疗12个月。
  • 主要终点为12个月时高频皮肤超声测得的RIF厚度减少>30%。
  • 2011年2月至2016年4月共入组60例患者,RIF为2级37例、3级22例、4级1例。

主要发现

  • RIF诊断至开始普伐他汀的平均间隔为17.1个月。
  • 18例患者在治疗不足11个月时停用普伐他汀,其中8例(13%)因与普伐他汀相关的≥2级不良事件停药。
  • 在基线和治疗12个月时接受高频超声疗效评估的40例患者中,15例(35.7%;95%CI 21.6%-52.0%)RIF厚度减少≥30%。
  • 12个月临床评估时,50%患者(n=21;95%CI 34.2%-65.8%)RIF严重程度下降,患者自我感知、情绪状态和社会功能显著改善。
  • 普伐他汀耐受性良好,3级毒性(肌痛)1例,2级毒性(肌痛/关节痛或食管炎)3例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The "PRAVACUR" phase 2 trial (NCT01268202) assessed the efficacy of pravastatin as an antifibrotic agent in patients with established cutaneous and subcutaneous radiation-induced fibrosis (RIF) after head and neck squamous cell carcinoma (HNSCC) radiation therapy and/or radiochemotherapy. METHODS AND MATERIALS: The main inclusion criteria were: NSCC in remission, grade ≥2 cutaneous and subcutaneous neck RIF (National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0), and no current treatment with statins or fibrates. Patients received pravastatin 40 mg/d for 12 months. The primary endpoint was reduction of RIF thickness by more than 30% at 12 months, as measured by cutaneous high-frequency ultrasonography. Secondary endpoints included RIF severity reduction, pravastatin tolerance, and quality of life. RESULTS: Sixty patients with grade 2 (n = 37), grade 3 (n = 22), or grade 4 (n = 1) RIF were enrolled from February 2011 to April 2016. The mean interval between RIF diagnosis and pravastatin initiation was 17.1 months. Pravastatin was stopped before 11 months of treatment in 18 patients (because of grade ≥2 adverse events related to pravastatin in 8 patients [13%]). In the 40 patients in whom pravastatin efficacy was assessed by high-frequency ultrasonography at baseline and at 12 months of treatment, a reduction of RIF thickness ≥30% was observed in 15 of 42 patients (35.7%; 95% confidence interval, 21.6%-52.0%). At the 12-month clinical evaluation, RIF severity was decreased in 50% of patients (n = 21; 95% confidence interval, 34.2%-65.8%), and the patients' self-perception, mood state, and social functioning were significantly improved. Pravastatin was well tolerated, with a very low occurrence of grade 3 toxicities (myalgia, n = 1) and grade 2 toxicities (myalgia/arthralgia or esophagitis, n = 3). CONCLUSIONS: This phase 2 prospective study supports the notion of radioinduced fibrosis reversibility. It showed that pravastatin (40 mg/d for 12 months) is an efficient antifibrotic agent in patients with grade ≥2 cutaneous and subcutaneous fibrosis after HNSCC radiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Bourgier C, Auperin A, Rivera S, et al. Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur. Int J Radiat Oncol Biol Phys. 2019. PMID: 30776452. doi:10.1016/j.ijrobp.2019.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。